144 related articles for article (PubMed ID: 26933749)
1. Biosimilars in Crohn's Disease and Ulcerative Colitis.
Wolf DC
Inflamm Bowel Dis; 2016 Apr; 22(4):994-7. PubMed ID: 26933749
[No Abstract] [Full Text] [Related]
2. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
Danese S; Fiorino G; Michetti P
J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
[TBL] [Abstract][Full Text] [Related]
3. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
Sullivan E; Piercy J; Waller J; Black CM; Kachroo S
PLoS One; 2017; 12(4):e0175826. PubMed ID: 28410403
[TBL] [Abstract][Full Text] [Related]
4. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
Peyrin-Biroulet L; Lönnfors S; Roblin X; Danese S; Avedano L
J Crohns Colitis; 2017 Jan; 11(1):128-133. PubMed ID: 27481878
[TBL] [Abstract][Full Text] [Related]
5. Review of Biosimilars of Adalimumab.
Kaushik VV
J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in inflammatory bowel disease.
Talathi S; Baig KRKK
J Dig Dis; 2020 Nov; 21(11):610-620. PubMed ID: 32920972
[TBL] [Abstract][Full Text] [Related]
7. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
8. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
9. Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists.
Baji P; Gulácsi L; Golovics PA; Lovász BD; Péntek M; Brodszky V; Rencz F; Lakatos PL
Value Health Reg Issues; 2016 Sep; 10():85-90. PubMed ID: 27881284
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
[TBL] [Abstract][Full Text] [Related]
12. IBD: Indication extrapolation for anti-TNF biosimilars.
Vande Casteele N; Sandborn WJ
Nat Rev Gastroenterol Hepatol; 2015 Jul; 12(7):373-4. PubMed ID: 26077557
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
McConachie S; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
16. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ
Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
[TBL] [Abstract][Full Text] [Related]
17. The use of biosimilars in paediatric inflammatory bowel disease.
Jongsma MME; Vulto A; de Ridder L
Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
[TBL] [Abstract][Full Text] [Related]
18. [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease].
Kull E; Beau P
Gastroenterol Clin Biol; 2002 Apr; 26(4):367-71. PubMed ID: 12070412
[TBL] [Abstract][Full Text] [Related]
19. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
Danese S; Fiorino G; Michetti P
J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in Crohn's disease.
Scheinberg M
J Crohns Colitis; 2014 Jul; 8(7):710. PubMed ID: 24365641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
